{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T23:20:02Z","timestamp":1785540002055,"version":"3.56.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008721","name":"University College London Hospitals NHS Foundation Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008721","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.euf.2025.12.016","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T21:10:32Z","timestamp":1767993032000},"page":"497-509","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Subsequent-line Systemic Therapy for Metastatic or Recurrent Penile Cancer: A Systematic Review of Efficacy, Toxicity, and Outcomes"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3473-4446","authenticated-orcid":false,"given":"Radion","family":"Garaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Ziada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Crozier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl H.","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussain M.","family":"Alnajjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine","family":"Alifrangis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Tsaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asif","family":"Muneer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2025.12.016_b0005","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.eururo.2023.02.027","article-title":"European Association of Urology-American Society of Clinical Oncology collaborative guideline on penile cancer: 2023 update","volume":"83","author":"Brouwer","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.12.016_b0010","unstructured":"National Comprehensive Cancer Network. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/penile.pdf."},{"key":"10.1016\/j.euf.2025.12.016_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103481","article-title":"Penile cancer: ESMO\u2013EURACAN clinical practice guideline for diagnosis, treatment and follow-up","volume":"9","author":"Muneer","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.euf.2025.12.016_b0020","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.urolonc.2013.10.007","article-title":"Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy","volume":"32","author":"Pond","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2025.12.016_b0025","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1200\/JCO.2010.29.5477","article-title":"Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study","volume":"28","author":"Pagliaro","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.12.016_b0030","doi-asserted-by":"crossref","first-page":"TPS14","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS14","article-title":"A phase II trial of pembrolizumab combined with platinum-based chemotherapy as first-line systemic therapy in advanced penile cancer: HERCULES (LACOG 0218) trial","volume":"41","author":"Maluf","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5_suppl","key":"10.1016\/j.euf.2025.12.016_b0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.2025.43.5_suppl.1","article-title":"EPIC-A: Phase II trial of cemiplimab plus standard of care chemotherapy followed by maintenance cemiplimab in locally advanced or metastatic penile carcinoma","volume":"43","author":"Bahl","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.12.016_b0040","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/jnci\/djad155","article-title":"Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors","volume":"115","author":"El Zarif","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.euf.2025.12.016_b0045","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/bju.12450","article-title":"Epidermal growth factor receptor\u2010targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis","volume":"113","author":"Carthon","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2025.12.016_b0050","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.eururo.2011.08.028","article-title":"Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study","volume":"60","author":"Di Lorenzo","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.12.016_b0055","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2025.12.016_b0060","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1136\/ijgc-2023-004486","article-title":"European Society of Gynaecological Oncology guidelines for the management of patients with vulvar cancer\u2014update 2023","volume":"33","author":"Oonk","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.euf.2025.12.016_b0065","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"371","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.euf.2025.12.016_b0070","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","article-title":"PRESS peer review of electronic search strategies: 2015 guideline statement","volume":"75","author":"McGowan","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.euf.2025.12.016_b0075","unstructured":"Wells GA, Shea BJ, O\u2019Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2025. https:\/\/wwwohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"10.1016\/j.euf.2025.12.016_b0080","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.euf.2025.12.016_b0085","unstructured":"Critical Appraisal Skills Programme. CASP checklists. https:\/\/casp-uk.net\/casp-tools-checklists\/systematic-review-checklist\/."},{"key":"10.1016\/j.euf.2025.12.016_b0090","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1177\/0300060519863546","article-title":"A phase II trial of cabazitaxel as second line chemotherapy in relapsed locally advanced and\/or metastatic carcinoma of the penis","volume":"47","author":"Challapalli","year":"2019","journal-title":"J Int Med Res"},{"key":"10.1016\/j.euf.2025.12.016_b0095","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3389\/fphar.2016.00487","article-title":"Prognostic and predictive factors in patients with advanced penile cancer receiving salvage (2nd or later line) systemic treatment: a retrospective, multi-center study","volume":"7","author":"Buonerba","year":"2016","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.euf.2025.12.016_b0100","doi-asserted-by":"crossref","DOI":"10.3389\/fruro.2023.1198980","article-title":"Feasibility and effectiveness of second-line chemotherapy with mitomycin C in patients with advanced penile cancer","volume":"3","author":"Draeger","year":"2024","journal-title":"Front Urol"},{"key":"10.1016\/j.euf.2025.12.016_b0105","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.urology.2014.12.049","article-title":"Treatment for metastatic penile cancer after first-line chemotherapy failure: analysis of response and survival outcomes","volume":"85","author":"Wang","year":"2015","journal-title":"Urology"},{"key":"10.1016\/j.euf.2025.12.016_b0110","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1177\/20514158211025913","article-title":"Longitudinal cohort analysis of patients with metastatic penile cancer treated in a large quaternary academic centre","volume":"16","author":"Liu","year":"2023","journal-title":"J Clin Urol"},{"key":"10.1016\/j.euf.2025.12.016_b0115","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40164-025-00629-4","article-title":"Efficacy and safety of immune checkpoint inhibitors in metastatic penile squamous cell carcinoma: a retrospective multicenter analysis","volume":"14","author":"Schieber","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.euf.2025.12.016_b0120","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.euo.2024.04.021","article-title":"Retifanlimab in advanced penile squamous cell carcinoma: the phase 2 ORPHEUS study","volume":"8","author":"Garc\u00eda Del Muro","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2025.12.016_b0125","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s43018-025-01004-2","article-title":"Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and\/or metastatic squamous cell carcinomas: a phase 2 basket trial","volume":"6","author":"Borcoman","year":"2025","journal-title":"Nat Cancer"},{"key":"10.1016\/j.euf.2025.12.016_b0130","doi-asserted-by":"crossref","first-page":"S720","DOI":"10.1016\/j.annonc.2021.08.111","article-title":"715P Nivolumab in pretreated metastatic penile squamous cell carcinoma: results of the penile cohort from the French AcS\u00e9 prospective program","volume":"32","author":"Pouessel","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euf.2025.12.016_b0135","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.2025.43.5_suppl.8","article-title":"Apatinib monotherapy for pretreated advanced squamous cell carcinoma of the penis: a phase II trial","volume":"43","author":"Zhang","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.12.016_b0140","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1200\/JCO.23.02233","article-title":"Final results from a phase I trial and expansion cohorts of cabozantinib and nivolumab alone or with ipilimumab for advanced\/metastatic genitourinary tumors","volume":"42","author":"Apolo","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.12.016_b0145","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.clgc.2015.08.001","article-title":"Panitumumab treatment for advanced penile squamous cell carcinoma when surgery and chemotherapy have failed","volume":"14","author":"Necchi","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euf.2025.12.016_b0150","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.urolonc.2018.10.016","article-title":"EGFR mono-antibody salvage therapy for locally advanced and distant metastatic penile cancer: clinical outcomes and genetic analysis","volume":"37","author":"Huang","year":"2019","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2025.12.016_b0155","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1159\/000315432","article-title":"Feasibility and activity of sorafenib and sunitinib in advanced penile cancer: a preliminary report","volume":"85","author":"Zhu","year":"2010","journal-title":"Urol Int"},{"key":"10.1016\/j.euf.2025.12.016_b0160","doi-asserted-by":"crossref","first-page":"32212","DOI":"10.18632\/oncotarget.4802","article-title":"Phase II study of docetaxel, cisplatin, and fluorouracil in patients with distantly metastatic penile cancer as first-line chemotherapy","volume":"6","author":"Zhang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.euf.2025.12.016_b0165","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1038\/bjc.2013.620","article-title":"Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK\/09\/001)","volume":"109","author":"Nicholson","year":"2013","journal-title":"Br J Cancer"},{"issue":"11 Pt B","key":"10.1016\/j.euf.2025.12.016_b0170","first-page":"E661","article-title":"Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis","volume":"110","author":"Di Lorenzo","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2025.12.016_b0175","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/ajcp\/aqad107","article-title":"Evaluation of programmed cell death ligand 1 expression in a contemporary cohort of penile squamous cell carcinoma and its correlation with clinicopathologic and survival parameters: a study of 134 patients","volume":"161","author":"Lobo","year":"2024","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.euf.2025.12.016_b0180","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.urolonc.2020.08.001","article-title":"Second line salvage systemic therapy for advanced penile cancer","volume":"40","author":"Chahoud","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2025.12.016_b0185","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.euf.2025.12.016_b0190","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1002\/cncr.35177","article-title":"Human papillomavirus infection affects treatment outcomes and the immune microenvironment in patients with advanced penile squamous cell carcinoma receiving programmed cell death protein 1 inhibitor\u2013based combination therapy","volume":"130","author":"Wei","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.euf.2025.12.016_b0195","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1200\/JCO.22.02894","article-title":"Atezolizumab with or without radiotherapy for advanced squamous cell carcinoma of the penis (the PERICLES study): a phase II trial","volume":"41","author":"de Vries","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.12.016_b0200","doi-asserted-by":"crossref","first-page":"883","DOI":"10.3390\/cancers17050883","article-title":"Immunotherapy in the management of penile cancer\u2014a systematic review","volume":"17","author":"Taghizadeh","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.euf.2025.12.016_b0205","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2112187","article-title":"Survival with cemiplimab in recurrent cervical cancer","volume":"386","author":"Tewari","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2025.12.016_b0210","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2025.12.016_b0215","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1200\/JCO.2025.43.5_suppl.9","article-title":"EPIC-B: phase II trial of cemiplimab as first-line treatment in advanced penile carcinoma","volume":"43","author":"Challapalli","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.12.016_b0220","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.48002","article-title":"Genomic profiles and clinical outcomes of penile squamous cell carcinoma with elevated tumor mutational burden","volume":"6","author":"Necchi","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.euf.2025.12.016_b0225","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1581556","article-title":"Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer","volume":"8","author":"Borcoman","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.euf.2025.12.016_b0230","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.eururo.2024.03.038","article-title":"Single-cell atlas of penile cancer reveals TP53 mutations as a driver of an aggressive phenotype, irrespective of human papillomavirus status, and provides clues for treatment personalization","volume":"86","author":"Elst","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.12.016_b0235","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41585-025-00994-z","article-title":"Treatment strategies in human papillomavirus-related advanced penile cancer","volume":"22","author":"Longoni","year":"2025","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euf.2025.12.016_b0240","first-page":"163","article-title":"Systemic treatment in metastatic penile cancer: current landscape, challenges, and future directions","volume":"18","author":"Garaz","year":"2025","journal-title":"Memo Mag Eur Med Oncol"},{"key":"10.1016\/j.euf.2025.12.016_b0245","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk\u2010of\u2010bias VISualization (robvis): an R package and Shiny web app for visualizing risk\u2010of\u2010bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925003955?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925003955?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:31:27Z","timestamp":1785529887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456925003955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2405456925003955"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2025.12.016","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Subsequent-line Systemic Therapy for Metastatic or Recurrent Penile Cancer: A Systematic Review of Efficacy, Toxicity, and Outcomes","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2025.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}